Joint Clinical Trials Office
The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)
Study Status:
Open to Enrollment
Primary Investigator:
Date: June 13, 2023
Phase II Multicenter Trial of Iberdomide as Maintenance Therapy for Multiple Myeloma Patients with Sub Optimal Response After Autologous Hematopoietic Stem Cell Transplant (AHCT)
Study Status:
Open to Enrollment
Primary Investigator:
Date: June 14, 2023
C-800-25: A Randomized, Open-Label, Phase 2 Study of Botensilimab (AGEN1181) as Monotherapy and in Combination with Balstilimab (AGEN2034) for the Treatment of Advanced, Refractory Microsatellite Stable Colorectal Cancer Without Liver Metastases
Study Status:
Open to Enrollment
Primary Investigator:
Date: June 14, 2023
A Phase I, Open-Label, Dose-Finding Study of TVB-2640 Administered in Combination with Enzalutamide (Xtandi) in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 14, 2023
A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-Expressing Metastatic Castrate Resistant Prostate Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 12, 2023
Brain Changes During Social Reward Psychotherapy for Mid- and Late-Life Suicidality: A Precision Imaging Trial
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 17, 2023
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 14, 2023
Expanded Access Program for belantamab mafodotin in Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 19, 2023
A Phase 1/2, Open-label, Dose escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP 3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 21, 2023
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Who
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 3, 2023